Epilepsy is a common and devastating neurological disease affecting more than 50 million people worldwide. Accumulating experimental and clinical evidence suggests that inflammatory pathways contribute to the development of seizures in various forms of epilepsy. In this context, while the activation of the PGE 2 EP2 receptor causes early neuroprotective and late neurotoxic effects, the role of EP2 receptor in seizures remains unclear. We investigated whether the systemic administration of the highly selective EP2 agonist ONO-AE1-259-01 prevented acute pentylenetetrazole (PTZ)-and pilocarpine-induced seizures. The effect of ONO-AE1-259-01 on cell death in the hippocampal formation of adult male mice seven days after pilocarpine-induced status epilepticus (SE) was also evaluated. ONO-AE1-259-01 (10 μg/kg, s.c.) attenuated PTZ-and pilocarpine-induced seizures, evidenced by the increased latency to seizures, decreased number and duration of seizures episodes and decreased mean amplitude of electrographic seizures. ONO-AE1-259-01 and pilocarpine alone significantly increased the number of pyknotic cells per se in all hippocampal subfields. The EP2 agonist also additively increased pilocarpine-induced pyknosis in the pyramidal cell layer of CA1 but reduced pilocarpine-induced pyknosis in the granule cell layer of the dentate gyrus (DG). Although the systemic administration of ONO-AE1-259-01 caused a significant anticonvulsant effect in our assays, this EP2 agonist caused extensive cell death. These findings limit the likelihood of EP2 receptor agonists being considered as novel potential anticonvulsant drugs.
Introduction
Accumulating experimental and clinical evidence suggests that the activation of inflammatory pathways contributes to the pathogenesis of seizures in various forms of epilepsy [1, 2] . In this sense, it has been shown that inflammatory mediators, such as cytokines and arachidonic acid derivatives play a role in seizures and epilepsy [3] [4] [5] [6] .PGE 2 , formed from arachidonic acid by the action of cyclooxygenases and PGE 2 synthase was primarily considered a pro-inflammatory prostanoid. However, current evidence suggests that it may have a much more complex role [7] . PGE 2 exerts its functions by binding mainly to four G-protein-coupled receptors known as E prostanoid (EP) receptors [1] [2] [3] [4] , that activate divergent signaling cascades. The EP2 receptor couples to G s and increases the intracellular levels of cAMP [8] , being highly expressed in neurons, microglial cells, and astrocytes of the piriform cortex, striatum and hippocampus [9, 10] . Recent evidence suggests that EP2 activation causes dual effects on neuronal viability in the time-course, i.e., while early stimulation is associated with neuroprotection, subsequent (late) stimulation is associated with increased neurotoxicity/inflammation [5, [11] [12] [13] . In this context, pretreatment with EP2 agonists reduces ischemia-, status-epilepticus (SE)-and NMDA-induced neuronal damage [10, [14] [15] [16] [17] . In contrast, it has been shown that EP2 receptor signaling after the seizures is detrimental, probably due its pro-inflammatory action [5, 11, 18, 19] . In line with this view, Jiang and colleagues [11, 20] have shown that the systemic administration of an EP2 antagonist approximately 2-4 h after the onset of a pilocarpine-induced SE decreases SE-induced mortality, weight loss, functional deficit, blood-brain barrier dysfunction, cytokine increase, gliosis, and neurodegeneration in the hippocampus [11, 20] .
Only a few studies have investigated the effect of EP2 receptor agonists and antagonists on seizure development. Oliveira and colleagues [4] have shown that the i.c.v. administration of the EP2 agonist butaprost increases the latency to pentylenetetrazole (PTZ)-induced myoclonic jerks and tonic-clonic seizures. Curiously, the EP2 antagonist TG6-10-1 does not modify diisopropylfluorophosphate-and pilocarpine-induced seizures acutely [20, 21] . Therefore, considering that (i) the effect of the highly selective [22] EP2 agonist ONO-AE1-259-01 on seizures is unknown, (ii) the anticonvulsant effect of a systemically administered EP2 agonist has not been previously investigated, (iii) the late effect of an EP2 receptor agonist administered before SE on the viability of hippocampal cells remains unknown, the present study aimed to investigate the effect of ONO-AE1-259-01 on PTZ-and pilocarpine-induced seizures and late morphological alterations in the hippocampal formation of mice.
Material and methods

Animals
Adult male Swiss mice (25-30 g), housed ten to a cage, and maintained under controlled light and environment (12:12 h light-dark cycle, 24 ± 1°C, 55% relative humidity) with free access to food (Guabi, Santa Maria, Brazil) and water, were used. All animals were obtained from the Animal House of the Federal University of Santa Maria.
All experiments reported in this study were conducted in accordance with the policies of the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23), revised in 1996, and with the institutional and national regulations for animal research. All efforts were made to reduce the number of animals used to a minimum, as well as to minimize their suffering (Committee on Care and Use of Experimental Animal Resources of the Federal University of Santa Maria authorization number: 078/2010).
Reagents
PTZ, pilocarpine and methylscopolamine were purchased from Sigma (St. Louis, MO, USA). ONO-AE1-259-01, an EP2 agonist, was kindly donated by Ono Pharmaceutical Co. (Osaka, Japan). ONO-AE1-259-01 was dissolved in dimethyl sulfoxide (DMSO, Sigma, St. Louis, MO, USA) and then diluted with sterile 0.9% NaCl, in such a way that DMSO concentration did not exceed 1%.
EEG recordings
Animals were surgically implanted with electrodes under stereotaxic guidance. Briefly, mice were deeply anesthetized with xylazine/ ketamine combination (10/100 mg/kg, respectively, i.p.) and four stainless steel screw electrodes (4.7 mm length) were placed over the parietal cortex, along with a ground lead positioned over the nasal sinus [23] . The electrode was fixed to the skull with dental acrylic cement. Chloramphenicol (200 mg/kg, i.p.) was administered immediately before the surgical procedure to prevent infection.
The experiments were performed seven days after surgery, according to Oliveira and colleagues [4] . The animals were allowed to habituate to a glass cage (30 cm L × 20 cm W × 20 cm H) for at least 10 min before the electroencephalographic (EEG) recording. The mice were then connected to the lead socket in a swivel inside a Faraday's cage. Routinely, a 15 min baseline recording was obtained to establish an adequate control period prior to drug administration according to each specific experimental protocol. The behavior of the animals was followed up, and EEG was concomitantly recorded using a digital encephalographer (LabChart 7.0, AD Instruments, Bella Vista, NSW, Australia). EEG signals were preamplified by a headmounted amplification system (Pinnacle Technology Inc., Lawrence, KS, USA), filtered (0.1-70.0 Hz, bandpass), digitized (sampling rate 256 Hz) and stored in a PC for off-line analysis. EEG recordings were analyzed for the appearance of seizure activity by identifying the following alterations in the recording leads: isolated sharp waves (≥ 1.5× baseline); multiple sharp waves (≥2× baseline) in brief spindle episodes (≥1 s, ≥5 s); multiple sharp waves (≥2× baseline) in long spindle episodes (≥5 s); spikes (≥2× baseline) plus slow waves; multispikes (≥2× baseline, ≥3 spikes/ complex) plus slow waves; major seizure (repetitive spikes plus slow waves obliterating background rhythm, ≥ 5 s). The behavior of each animal was recorded during the whole EEG acquisition period with a digital camera, and videotaped recordings were used to identify nonconvulsive seizures and possible artifacts. Rhythmic scratching of the electrode headset by the animal rarely caused artifacts. These recordings were easily identified and discarded.
EEG and videotape recordings were used to assess the following variables: latency to myoclonic jerks (only for PTZ-injected animals), latency to generalized tonic-clonic seizures, latency to SE (only for pilocarpine-injected animals), number of seizure episodes and total time spent seizing (only for PTZ-injected animals), mean basal amplitude, mean amplitude during seizures and number of epileptiform events. Digitized data from the whole recording were divided in 3-s segments, and a 1-s sample from each segment was used to determine the wave amplitude. An epileptiform event was defined as a highamplitude (2 × baseline) rhythmic discharge containing a burst of slow waves, spike wave and/or polyspike-wave components and lasting b 5 s [24] . These events were detected by using an algorithm of LabChart 7.0.
The severity of PTZ-induced seizures was scored by the modified Racine scale [25] , as follows: (1) sudden behavioral arrest and/or motionless staring; (2) facial jerking with muzzle or muzzle and eye; (3) neck jerks; (4) clonic seizure in a sitting position; (5) convulsion including clonic and/or tonic-clonic seizure while lying on the belly and/or pure tonic seizure; and (6) convulsion including clonic and/or tonic-clonic seizure while lying on the side and/or wild jumping. The severity of pilocarpine-induced seizures was evaluated by the Racine scale adapted by Meurs and colleagues [26] , as follows: (0) normal, nonepileptic activity; (1) mouth and facial movements, hyperactivity, grooming, sniffing, scratching, wet dog shakes; (2) head nodding, staring, tremor; (3) forelimb clonus, forelimb extension; (4) rearing, salivating, tonic-clonic activity; and (5) falling, SE. The Racine scale adapted by Meurs and colleagues was used to evaluate the severity of pilocarpine-induced seizures because it includes all behavioral changes observed in limbic seizure models [26] . The number of seizure episodes was calculated by summing the number of seizure events rated as stage 5 and 6 by the Racine scale and stage 4 and 5 by the Meurs scale. The total time spent in seizures was calculated by sum of the duration of all seizures during the observation time [27] .
Experimental protocol 2.4.1. Effect of ONO-AE1-259-01 on PTZ-induced seizures
On the day of the experiment each animal was individually transferred to the glass observation cage, connected to the swivel socket and, after a 15 min baseline recording (control period), ONO-AE1-259-01 (10 μg/kg, s.c.) or vehicle (1% DMSO in sterile 0.9% NaCl, s.c.) were administered. The animals were injected with PTZ (60 mg/kg, i.p.), 30 min after the administration of the EP2 agonist and followed up for 30 min for the appearance of seizures by electrographic and behavioral methods. Drug doses and time between injections were selected based on pilot experiments and a dose-effect curve for ONO-AE1-259-01 ( Fig. 1 ).
Effect of ONO-AE1-259-01 on pilocarpine-induced seizures
On the day of the experiment each animal was individually transferred to the glass observation cage, connected to the swivel socket and a 15 min baseline recording was obtained to establish an adequate control period. To minimize peripheral cholinergic effects of pilocarpine mice were injected with methylscopolamine (1 mg/kg, i.p., in 0.9% NaCl). Five minutes after the injection of methylscopolamine, animals were injected with ONO-AE1-259-01 (10 μg/kg, s.c.) or vehicle (1% DMSO in sterile 0.9% NaCl, s.c.). Pilocarpine (185 mg/kg, i.p.) was administered 30 min thereafter to induce SE. SE was considered as a seizure activity that lasted 30 min. SE was terminated by administering diazepam (20 mg/kg, i.p.).
Histological analysis
A subset of animals (5-6 per group) subjected to exactly the same experimental procedures described above for EEG recording, except for anesthesia and electrode implanting, was used to investigate the effect of ONO-AE1-259-01 on the neuronal death induced by pilocarpine (185 mg/kg, i.p.). Control animals received methylscopolamine, saline and diazepam, but not pilocarpine. Mice were deeply anesthetized (100 mg/kg ketamine, 10 mg/kg xylazine, i.p.) and transcardially perfused with ice-cold 0.1 M phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA) solution in PBS seven days after SE. The cranial vault was entered by removal of the calvarium, the brain was removed and immediately placed in 4% PFA for 18-24 h at 4°C. The brain was processed by means of the usual techniques for embedding in paraffin, and 6 μm-thickness sections were cut (Leica RM2235 -Manual Rotary Microtome, Solms, Germany). At least four sections were mounted on histological slides and stained with cresyl violet to analyze the microscopic alterations present. The stain identifies the somas of neurons (violet-purple color), allowing pyknotic cells identification (a measure of cell death).
The images were obtained with a video camera coupled to a trinocular microscope (Leica DMI 400B) and connected to a microcomputer. The cells were displayed in sagittal view of the mouse brain (ML 1.2 mm from bregma). The quantitative analysis was performed using image analysis system (Image J 1.44p National Institutes of Health, Bethesda, MD), from which the number of pyknotic and normal cells in the pyramidal layer of the CA1 and CA3 subfields, granule cell layer of dentate gyrus (DG) and hilus (H) in two adjacent fields (× 40) for the different groups was evaluated, in each section. The average number of morphologically normal neurons and pyknotic cells per hippocampal formation subfield was calculated using the four sections. The percent of pyknotic cells in each hippocampal formation subfield was calculated from resulting mean values, and used for subsequent statistical analysis. Visual assessment and neuron counting were carried out blindly with respect to the pharmacological treatment by a single rater.
Statistical analysis
Latency to myoclonic jerks and to generalized tonic-clonic seizures, and total time spent seizing were analyzed by Mann-Whitney test. These data are presented as median and interquartile range. Number of seizures was analyzed by Student t Test and mean amplitude of EEG recordings was analyzed by repeated measures ANOVA. Data are expressed as mean and standard error of the mean (S.E.M.). Morphometric data (percent of pyknotic cells) were analyzed by a mixed model ANOVA, considering the hippocampal subfield factor as repeated measures. Post hoc analysis was carried out by multiple comparisons .000, p b 0.01, D) , but did not alter the Racine scale (U = 7.000, p N 0.05, E).
Representative EEG patterns of vehicle and ONO-AE1-259-01-treated groups are presented in Fig. 3A and B, respectively. PTZ injection caused the appearance of multispike plus slow waves and major seizure activity, which coincided with myoclonic jerks. Generalized seizures appeared in the EEG recordings as the major seizure activity, and were characterized by 2-3 Hz high amplitude activity (Fig. 3A′ and B′, for vehicle and ONO-AE1-259-01-treated groups, respectively).
Quantitative analysis of ictal EEG trace amplitude and number of epileptiform events after PTZ injection are shown in Fig. 3C and D, Fig. 3D ] when compared with vehicle group. Quantification of electroencephalographic wave amplitude revealed no difference between vehicle and ONO-AE1-259-01-injected animals before PTZ injection. 
Effect of ONO-AE1-259-01 on pilocarpine-induced seizures
Histological analysis
Since ONO-AE1-259-01 decreased both PTZ-and pilocarpineinduced seizures and there are several studies in the literature showing that EP2 activation mediates early neuroprotection [7, 10, 16, 17] and later neurotoxicity after injury [5, 11, 20] , we tested whether ONO-AE1-259-01 alters pilocarpine-induced cell death in the hippocampal formation on the seventh day after SE. Fig. 6 shows the effect of ONO-AE1-259-01 (10 μg/kg, s.c.) on the number of normal (white arrowhead) and pyknotic cells (black arrowhead) in the pyramidal cell layer of the CA1 (Fig. 6B) and CA3 (Fig. 6C ) subfields and granule cell layer of the dentate gyrus (DG) and hilus (H) (Fig. 6D ) of mice subjected to pilocarpine-induced SE (185 mg/kg, i.p.). Three-way ANOVA, considering the hippocampal formation subfield factor as repeated measures revealed a significant interaction among pharmacological treatment (vehicle or ONO-AE1-259-01), convulsant (saline or pilocarpine) and hippocampal formation subfield (CA1, CA3, DG or hilus) [F(3,48) = 6.44; p b 0.05, Fig. 6 ]. Post hoc analyses on data from each hippocampal subfield revealed that ONO-AE1-259-01 (Fig. 6 B2, C2, D2 ) and pilocarpine (Fig. 6 B3, C3, D3 ) increased the percentage of pyknotic cells, per se, in all hippocampal formation subfields. Interestingly, while ONO-AE1-259-01 additively increased pilocarpine-induced pyknosis in the pyramidal cell layer of CA1 (Fig. 6 B4) , it significantly reduced pilocarpine-induced pyknosis in the granule cell layer of the DG (Fig. 6 D4) .
Discussion
In the current study we showed that the EP2 agonist ONO-AE1-259-01 attenuates PTZ-and pilocarpine-induced seizures as characterized by the increased latency to seizure, decreased number and duration of seizures episodes and decreased mean amplitude of electrographic seizures. However, ONO-AE1-259-01 induced neuronal death per se in the hippocampus and additively increased pilocarpine-induced neuronal death in the pyramidal cell layer of the CA1 subfield. ONO-AE1-259-01 reduced the number of pyknotic cells in the granule cell layer of the DG of animals injected with pilocarpine.
There is pharmacological evidence that PGE 2 facilitates the seizures induced by PTZ [28] and methylmalonate [27] . It has been shown that EP1, EP3 and EP4 antagonists and the EP2 agonist butaprost reduce PTZ-induced seizures [4] . In line with this view, the currently reported inhibition of PTZ-induced seizures by EP2 agonist ONO-AE1-259-01 not only fully agrees with the previous finding that the i.c.v. administration of the EP2 agonist butaprost decreases PTZ-induced seizures in rats [4] , but extends these findings to mice and reveals that the systemic administration of an EP2 agonist decreases PTZ-and pilocarpine-induced seizures, two distinct acute seizure models.
ONO-AE1-259-01 is a highly selective EP2 receptor agonist that has no detectable affinity for other prostaglandin receptors [22] . In addition, it binds to the EP2 receptor (Ki = 3 nM) with higher affinity than does PGE 1 , 16,16-dimethyl-PGE 2 , 11-deoxy-PGE 1 , butaprost, or AH-6809 (Ki = 10, 17, 45, 110, and 350 nM, respectively) [29] [30] [31] [32] . Therefore, we presume that the effects of ONO-AE1-259-01 reported herein are due to an action at the EP2 receptors. Interestingly, we observed that animals subjected to electrode implantation for posterior EEG analysis required a dose of 10 μg/kg of ONO-AE1-259-01 to decrease seizures. This contrasts with the initial findings that naive animals required a dose of 3 μg/kg of ONO-AE1-259-01 to decrease behavioral seizures (Fig. 1) . Therefore, it seems that an existing inflammatory process decreases the sensitivity to the anticonvulsant effect of the EP2 agonist. This may occur because inflammation increases seizure susceptibility per se [2, 5, 33, 34] . It also remains to be determined whether EP2 receptors present in neuronal, astrocyte or microglial cells are involved in the current anticonvulsant effect of ONO-AE1-259-01, as well as the cellular mechanisms underlying this effect. Although a significant anticonvulsant effect for ONO-AE1-259-01 was observed in our assays, from the drug development point of view, the cell death induced by this EP2 agonist (see below) limits its potential as target for drug development, particularly if a class effect confirms.
It is well known that pilocarpine-induced SE leads to neuronal cell death, gliosis, increased abnormal neurogenesis and mossy fiber sprouting in the hippocampus [35, 36] . In this study we found increased cell pyknosis seven days after pilocarpine-induced SE in the hippocampus. Interestingly, while ONO-AE1-259-01 increased the number of pyknotic cells in all hippocampal formation per se, it decreased the number of pyknotic cells in the dentate gyrus of animals injected with pilocarpine. Similar to our data, there are seemingly conflicting results in the literature suggesting that the EP2 receptor may cause both neuroprotection and neurotoxicity. In fact, while the pre-administration of the EP2 agonist ONO-AE1-259-01 reduces, the genetic ablation of the EP2 receptor increases the infarct volume induced by transient ischemia in mice [7] , suggesting a neuroprotective role for the EP2 receptor. In addition, EP2 receptor activation decreases pilocarpine-and NMDAinduced neuronal death in the CA1 region, evaluated one day after injury [16, 17] . McCullough and colleagues [10] have also observed a marked protective effect of the EP2 agonist butaprost in neuronal and organotypic hippocampal cultures subjected to glutamate or oxygenglucose deprivation (OGD) toxicity, 24 h after injury. The EP2 receptor has been classically coupled to Gs activation, increasing cAMP intracellular levels [8] . PKA activation by cAMP has been reported to be neuroprotective in various types of neurons [37, 38] . Such a neuroprotective effect has been attributed to several mechanisms, including reduced release of Ca 2+ from the endoplasmic reticulum [39] , activation of glutamate transporters [40] and suppression of the activity of neuronal nitric oxide synthase [41] . On the other hand, there are studies showing that EP2 receptor increases oxidative stress and neurotoxicity in animal models of chronic inflammation, SE and neurodegeneration, which involve proinflammatory mediators and microglial activation [18] [19] [20] 42, 43] . In fact, EP2 receptor activation by PGE 2 or butaprost exacerbates the rapid induction of proinflammatory COX-2, iNOS, IL-1β and IL-6 and regulates microglial activation through cAMP-exchange protein activated by cAMP (Epac)-mediated mechanisms [18, 19] , creating an environment that has been shown to damage the brain tissue [5, 12] . Moreover, the ablation of EP2 receptor protects intermediate progenitor cells from innate immune activation [44] . The study by Johansson and colleagues [45] has shown that multiple immune factors in blood and inflammatory endothelial factors are reduced in mice with global deletion of EP2 after systemic administration of LPS. Cell-specific deletion of EP2 receptor in monocyte lineage cells, including macrophages, monocytes and microglia, blunts LPS-mediated innate immune response peripherally and in the central nervous system (CNS), as well as in the MPTP model of secondary microglial inflammation in the substantia nigra [45] . Likewise, Jiang and colleagues [11, 20] have shown that the administration of an EP2 receptor antagonist after 2-4 h pilocarpineinduced SE (coinciding with exacerbation of inflammation and COX-2 induction), mitigates many of the deleterious consequences of SE, including delayed mortality, weight loss, functional deficit, opening of the blood-brain barrier, formation of a cytokine storm, gliosis, and neurodegeneration in the hippocampus. As reviewed by Jiang and Dingledine [46] , it is possible that the multiplicity of signal transduction mechanisms engaged by EP2, involving both G-protein-dependent and -independent pathways (cAMP-and β-arrestin-mediated, respectively), endow this receptor with diverse physiologic and pathological functions. This comprehends the differential activation of intracellular cAMP-activated cascades, such as Epac and PKA, which could contribute for such a diversity of responses, including in temporal terms. In line with this view, EP2 activity via cAMP-PKA rote would provide neuroprotection while EP2 activity via cAMP-Epac role would cause neurotoxicity [12] . In addition, such a different profile of post-receptor coupling would also result in different responses depending on the differential activation of EP2 receptors in microglia and neurons [47, 48] . Therefore, it is possible that both mechanisms underlie the currently reported deleterious and pro-survival effects of ONO-AE1-259-01 on neurons of the CA1 and DG regions of animals injected with pilocarpine. Moreover, ONO-AE1-259-01 may have stimulated DG neurogenesis, masking the ability to detect neuronal loss in these animals. This is particularly interesting because pilocarpine increases DG neurogenesis [36] and the activation of EP2 receptor has been implicated in PC3 cell proliferation [47] . Therefore, specific studies have to be performed in order to determine whether the ONO-AE1-259-01-induced decrease of cell death in the DG seven days after pilocarpine injection is due a proliferative or a neuroprotective action of the EP2 agonist. Recent studies have emphasized the importance of the time window in which EP2 receptors are stimulated to cause neuroprotection or neurotoxicity [5, [11] [12] [13] . According to this view, early stimulation is associated with neuroprotection, subsequent (late) stimulation is associated with increased neurotoxicity/inflammation. Although in the current study the EP2 agonist was given before pilocarpine-induced SE, it predominantly caused neurotoxicity. However, since there is no information about the half-life of ONO-AE1-259-01 in mice, we cannot rule out that the currently reported neurotoxic effect of this EP2 agonist is due to a long-term effect of the compound, and further studies are needed to clarify this point. At last, it is well known that PTZ-induced seizures results in the production of a large amount of endogenous prostaglandins, as such PGD 2 , PGF 2α and PGE 2 [49, 50] . PGD 2 has a consistent anticonvulsant action mediated by DP1 receptor [49] which, similarly to the EP2 receptor, is coupled to Gs protein and increases cAMP levels. Therefore, we cannot rule out a possible interaction between endogenous prostanoids, particularly PGD 2 , and the exogenous EP2 agonist at the post-receptor level, further increasing cAMP levels. Notwithstanding, we ratify that current evidence indicates that stimulation of EP2 receptors are not a safe strategy to decrease seizures.
Conclusions
The highly selective EP2 agonist ONO-AE1-259-01 decreases PTZand pilocarpine-induced seizures. Although the systemic administration of ONO-AE1-259-01 caused a significant anticonvulsant effect in our assays, this EP2 agonist caused extensive cell death. These findings limit the likelihood of EP2 receptor agonists being considered as novel potential anticonvulsant drugs.
